drugset / Trial / NCT01299558

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

NCT01299558

Phase 1 Completed 16 enrolled GlaxoSmithKline
Non-randomizedCrossoverOpen-labelOther

Summary

This study is being done to look at the absolute bioavailability of fluticasone furoate and GW642444 inhalation powder when administered in healthy subjects. Bioavailability is determined by measuring the amount of the dose of inhaled medication that reaches the circulation; the amount of inhaled fluticasone furoate and GW642444 powder will be compared to the medication administered intravenously (where bioavailability is 100%).

Timeline

Start
2010-05-17
Primary completion
2010-07-15
Completion
2010-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 250 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 800 ug Inhaled
Subject Vilanterol Other / unclassified 55 ug Inhaled
Subject Vilanterol Other / unclassified 100 ug Inhaled

Indications